Evidence map›Paper›PMID 36064984›Full record

ArticleJournal of cancer research and clinical oncology2023

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy.

Jaewon Hyung, Hyunseok Yoon, Chang-Min Choi, Shinkyo Yoon, Dae Ho Lee, Sang-We Kim, Hyeong-Ryul Kim, Su Ssan Kim, Si Yeol Song, Jae Cheol Lee

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jaewon HyungDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Hyunseok YoonDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Chang-Min ChoiDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Shinkyo YoonDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Dae Ho LeeDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Sang-We KimDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Hyeong-Ryul KimDepartment of Thoracic and Cardiovascular Surgery, University of Ulsan College of Medicine, Seoul, Korea.
Su Ssan KimDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Si Yeol SongDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jae Cheol LeeDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. jclee@amc.seoul.kr.
University of Ulsan · KRAsan Medical Center · KRUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWhether prior radiotherapy (RT) affects the response of EGFR-mutated non-small cell lung cancer (NSCLC) to EGFR tyrosine kinase inhibitor (TKI) remains elusive.

methodsPatients with EGFR-mutated NSCLC treated with EGFR TKIs who recurred after curative treatment at Asan Medical Center, Seoul, Korea were included. The progression-free survival (PFS) and overall survival (OS) from the initiation of EGFR TKI in patients who recurred after definitive RT were analyzed and compared to the outcomes of RT-naïve patients with advanced NSCLC treated with EGFR TKIs from previously reported prospective clinical trial results.

resultsA total of 60 patients who recurred after definitive RT were included. The median age was 70 years (range, 38-88), with 24 patients (40.0%) being males. Among the 60 patients, 52 patients (86.7%) had exon 19 deletion or L858R mutation, with 49 patients (81.7%) receiving gefitinib as the first-line EGFR TKI. The median PFS and OS from the initiation of EGFR TKI were 10.4 months (95% confidence interval [CI], 7.4-13.2) and 21.3 months (95% CI, 13.4-28.8), respectively.

conclusionThe EGFR TKI efficacy in EGFR-mutated patients with NSCLC who recurred after RT was comparable with that in historic controls of RT-naïve patients with advanced NSCLC treated with EGFR TKIs, indicating that RT may not affect EGFR TKI efficacy.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedErbB ReceptorsFemaleHumansMaleMutationNeoplasm Recurrence, LocalProspective StudiesProtein Kinase InhibitorsTyrosine Kinase InhibitorsErbB ReceptorsProtein Kinase InhibitorsTyrosine Kinase InhibitorsConcurrent chemoradiationEpidermal growth factor receptor mutationNon-small cell lung cancerRadiotherapyTyrosine kinase inhibitors

Identifiers

PMID36064984
PMCPMC11797761
OpenAlexW4294631397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.